Replimune Group (NASDAQ: REPL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Replimune Group reported 19 open-market sales of 243,285 shares ($2.5m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 9 November 2026 | Slattery Joseph P | Director | Open-market sale | −5,200 | $21.80 | 1,467 | Form 4 |
| 2 November 2026 | Dhingra Kapil | Director | Option exercise | +43,169 | $1.75 | 43,169 | Form 4 |
| 2 November 2026 | Dhingra Kapil | Director | Open-market sale | −21,500 | $19.00 | 21,669 | Form 4 |
| 20 August 2026 | Astley-Sparke Philip | Director | Gift | −50,000 | — | 1,362,414 | Form 4 |
| 17 August 2026 | Hill Emily Luisa | Chief Financial Officer | Open-market sale | −9,256 | $14.28 | 215,852 | Form 4 |
| 10 August 2026 | Schwendenman Andrew | Chief Accounting Officer | Open-market sale | −7,632 | $12.97 | 99,425 | Form 4 |
| 10 August 2026 | Xynos Konstantinos | Chief Medical Officer | Open-market sale | −11,447 | $12.97 | 224,215 | Form 4 |
| 10 August 2026 | Hill Emily Luisa | Chief Financial Officer | Open-market sale | −11,448 | $12.97 | 225,108 | Form 4 |
| 10 August 2026 | Patel Sushil | Chief Executive Officer | Open-market sale | −39,341 | $12.97 | 708,151 | Form 4 |
| 1 June 2026 | Sarchi Christopher | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −12,000 | $9.24 | 180,962 | Form 4 |
| 18 May 2026 | Hill Emily Luisa | Chief Financial Officer | Open-market sale | −7,812 | $5.08 | 236,556 | Form 4 |
| 18 May 2026 | Patel Sushil | Chief Executive Officer | Open-market sale | −37,324 | $5.08 | 747,492 | Form 4 |
| 18 May 2026 | Astley-Sparke Philip | Director | Open-market sale | −17,657 | $5.08 | 1,412,414 | Form 4 |
| 18 May 2026 | Sarchi Christopher | Chief Commercial Officer | Open-market sale | −8,626 | $5.08 | 192,962 | Form 4 |
| 18 May 2026 | Schwendenman Andrew | Chief Accounting Officer | Open-market sale | −7,894 | $5.08 | 107,057 | Form 4 |
| 18 May 2026 | Xynos Konstantinos | Chief Medical Officer | Open-market sale | −14,023 | $5.08 | 235,662 | Form 4 |
| 2 April 2026 | Sarchi Christopher | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −6,500 | $8.01 | 151,588 | Form 4 |
| 1 April 2026 | Hill Emily Luisa | Chief Financial Officer | Grant or award | +50,000 | — | 244,368 | Form 4 |
| 1 April 2026 | Patel Sushil | Chief Executive Officer | Grant or award | +251,240 | — | 784,816 | Form 4 |
| 1 April 2026 | Schwendenman Andrew | Chief Accounting Officer | Grant or award | −36,667 | — | 114,951 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Replimune Group page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.